BTAI
BioXcel Therapeutics, Inc.Company Information
- Company Name
- BioXcel Therapeutics, Inc.
- CIK
- CIK0001720893
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- BTAI: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- BTAI
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-05-20
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 39,669
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 6,159,753
- Shares outstanding
- 30,300,000
- Ownership
- 20.33%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -93.45%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Related Party | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Nonrelated Party | 0 | 10 | 10 | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 13 | 17 | 28 | 36 | 17 | 31 | 30 | 40 | 56 | 74 | 65 | 90 | ||||||
| Restricted Cash Current | 1 | 0 | 0 | 1 | 1 | - | 0 | 0 | - | - | - | - | ||||||
| Receivables Net Current | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 1 | 0 | 0 | 1 | ||||||
| Inventory Net | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 2 | ||||||
| Prepaid Expense And Other Assets Current | 3 | 4 | 4 | 6 | 5 | 5 | 5 | 4 | 3 | 2 | 3 | 4 | ||||||
| Other Assets Current | 11 | 12 | 11 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | ||||||
| Assets Current | 29 | 34 | 45 | 44 | 25 | 38 | 37 | 48 | 64 | 81 | 72 | 99 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | ||||||
| Other Assets Noncurrent | - | - | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 29 | 34 | 45 | 45 | 26 | 39 | 38 | 49 | 65 | 82 | 74 | 100 | ||||||
Liabilities Current | ||||||||||||||||||
| Due To Related Parties Current | - | - | - | - | - | - | - | - | - | - | - | 1 | ||||||
| Accounts Payable Current | 19 | 16 | 15 | 16 | 17 | 15 | 16 | 15 | 13 | 17 | 14 | 11 | ||||||
| Accrued Liabilities Current | 4 | 6 | 4 | 4 | 5 | 4 | 6 | 10 | 13 | 14 | 12 | 27 | ||||||
| Interest Payable Current | - | - | - | - | - | - | - | - | 0 | 0 | 1 | 1 | ||||||
| Other Liabilities Current | - | - | - | - | - | - | - | - | - | - | - | 1 | ||||||
| Long Term Debt Current | 104 | 22 | 25 | 17 | 11 | 6 | 0 | - | - | - | - | - | ||||||
| Liabilities Current | 137 | 55 | 54 | 38 | 33 | 26 | 22 | 26 | 27 | 31 | 27 | 39 | ||||||
| Operating Lease Liability Noncurrent | - | - | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 | 1 | ||||||
| Derivative Liabilities Noncurrent | 7 | 7 | 2 | 4 | 3 | 3 | 7 | 4 | 9 | 21 | 2 | 2 | ||||||
| Long Term Debt Noncurrent | 0 | 78 | 85 | 92 | 97 | 100 | 103 | 104 | 103 | 102 | 101 | 99 | ||||||
| Liabilities | 144 | 140 | 140 | 134 | 133 | 129 | 131 | 135 | 140 | 155 | 130 | 141 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | - | 0 | - | - | - | - | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 632 | 627 | 625 | 619 | 569 | 567 | 557 | 554 | 551 | 545 | 534 | 528 | ||||||
| Retained Earnings Accumulated Deficit | -747 | -733 | -720 | -708 | -677 | -657 | -650 | -639 | -626 | -617 | -591 | -568 | ||||||
| Stockholders Equity | -115 | -106 | -95 | -89 | -108 | -90 | -93 | -86 | -74 | -72 | -57 | -41 | ||||||
| Liabilities And Stockholders Equity | 29 | 34 | 45 | 45 | 26 | 39 | 38 | 49 | 65 | 82 | 74 | 100 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 100 | 100 | 100 | ||||||
| Common Stock Shares Issued | 31 | 27 | 22 | 20 | 7 | 5 | 3 | 3 | 3 | 2 | 2 | 2 | ||||||
| Shares Outstanding | 31 | 27 | 22 | 20 | 7 | 5 | 3 | 3 | 3 | 2 | 2 | 2 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialBioXcel Therapeutics, Inc. (BTAI) — SEC Financial Statements & Analysis
BioXcel Therapeutics, Inc. (BTAI) is a pharmaceutical preparations company, incorporated in DE. BioXcel Therapeutics, Inc. trades on Nasdaq as: BTAI. BioXcel Therapeutics, Inc. (BTAI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, On profitability, BioXcel Therapeutics, Inc. posts a gross margin of 53.10%, an operating margin of -6054.72%, a net margin of -9549.87%, a Return on Equity (ROE) of 63.52%, and a Return on Assets (ROA) of -259.62%. Per share, it reports EPS of $-2.34, diluted EPS of $-2.34, free cash flow per share of $-1.68, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -14.52% year-over-year, net income growth of 39.08% year-over-year, and EPS growth of -64.00% year-over-year. On the balance sheet, it maintains a current ratio of 0.21x, a quick ratio of 0.18x, working capital of $-108.45M, a debt-to-equity ratio of -1.25x, a debt ratio of 5.01, an interest coverage ratio of -2.61x, free cash flow of $-50.90M (TTM), and net debt of $90.65M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-2.34
- ROE TTM
- 63.52%
- ROA TTM
- -259.62%
- Debt To Equity
- -1.25x
- Free Cash Flow TTM
- $-50.90M
- Net Revenue TTM Growth 1Y
- -14.52%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is BioXcel Therapeutics, Inc. in?
BioXcel Therapeutics, Inc. (BTAI) operates in the Pharmaceutical Preparations industry.
What exchange does BTAI trade on?
BioXcel Therapeutics, Inc. (BTAI) trades on the Nasdaq.
Where is BioXcel Therapeutics, Inc. incorporated?
BioXcel Therapeutics, Inc. is incorporated in DE.
When was BioXcel Therapeutics, Inc. (BTAI)'s most recent SEC filing?
BioXcel Therapeutics, Inc. (BTAI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is BTAI's EPS (earnings per share)?
BioXcel Therapeutics, Inc. (BTAI)'s trailing twelve month EPS is $-2.34 as of 2026-06-30.
What is BTAI's ROE (return on equity)?
BioXcel Therapeutics, Inc. (BTAI)'s trailing twelve month Return on Equity (ROE) is 63.52% as of 2026-06-30.
What is BTAI's ROA (return on assets)?
BioXcel Therapeutics, Inc. (BTAI)'s trailing twelve month Return on Assets (ROA) is -259.62% as of 2026-06-30.